secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neumora Therapeutics, Inc. (NMRA)
CIK:        0001885522
Form:       8-K/A
Filed at:   2025-04-11T23:59:59+00:00
Accession:  0000950170-25-053303
Event type: other_material
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Neumora revises stock option repricing to use closing price on May 28, 2025 annual meeting date
--------------------------------------------------------------------------------

- Originally repriced using Feb 13, 2025 closing price; revised on Apr 7, 2025 to use closing price on scheduled annual meeting date (May 28, 2025).
- Repricing applies to eligible options held by board, named executive officers, and other service providers under 2023 and 2020 equity plans.
- Reduced exercise price requires stockholder approval; options must be exercised on/after Aug 13, 2026 while service continues.
- Except for the closing price date, all other terms of repriced options remain unchanged.
- Annual stockholder meeting scheduled for May 28, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1885522/000095017025053303/0000950170-25-053303-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1885522/000095017025053303/nmra-20250213.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-053303

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer